JP6448645B2 - メランコリアの特徴を伴う抑うつ障害を処置するための、カッパ−活性を伴うオピオイド受容体拮抗薬およびボルチオキセチンの使用 - Google Patents

メランコリアの特徴を伴う抑うつ障害を処置するための、カッパ−活性を伴うオピオイド受容体拮抗薬およびボルチオキセチンの使用 Download PDF

Info

Publication number
JP6448645B2
JP6448645B2 JP2016540981A JP2016540981A JP6448645B2 JP 6448645 B2 JP6448645 B2 JP 6448645B2 JP 2016540981 A JP2016540981 A JP 2016540981A JP 2016540981 A JP2016540981 A JP 2016540981A JP 6448645 B2 JP6448645 B2 JP 6448645B2
Authority
JP
Japan
Prior art keywords
vortioxetine
activity
nalmefene
opioid antagonist
opioid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016540981A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016540030A5 (enExample
JP2016540030A (ja
Inventor
サンチェス モリロ，コニー
サンチェス モリロ，コニー
エヌ． スマジン，ジェナディー
エヌ． スマジン，ジェナディー
Original Assignee
ハー・ルンドベック・アクチエゼルスカベット
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52146489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6448645(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ハー・ルンドベック・アクチエゼルスカベット filed Critical ハー・ルンドベック・アクチエゼルスカベット
Publication of JP2016540030A publication Critical patent/JP2016540030A/ja
Publication of JP2016540030A5 publication Critical patent/JP2016540030A5/ja
Application granted granted Critical
Publication of JP6448645B2 publication Critical patent/JP6448645B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016540981A 2013-12-20 2014-12-18 メランコリアの特徴を伴う抑うつ障害を処置するための、カッパ−活性を伴うオピオイド受容体拮抗薬およびボルチオキセチンの使用 Active JP6448645B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201300710 2013-12-20
DKPA201300710 2013-12-20
DKPA201400590 2014-10-16
DKPA201400590 2014-10-16
PCT/EP2014/078515 WO2015091833A1 (en) 2013-12-20 2014-12-18 Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features

Publications (3)

Publication Number Publication Date
JP2016540030A JP2016540030A (ja) 2016-12-22
JP2016540030A5 JP2016540030A5 (enExample) 2018-01-18
JP6448645B2 true JP6448645B2 (ja) 2019-01-09

Family

ID=52146489

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016540981A Active JP6448645B2 (ja) 2013-12-20 2014-12-18 メランコリアの特徴を伴う抑うつ障害を処置するための、カッパ−活性を伴うオピオイド受容体拮抗薬およびボルチオキセチンの使用

Country Status (14)

Country Link
US (1) US10376506B2 (enExample)
EP (1) EP3082815B1 (enExample)
JP (1) JP6448645B2 (enExample)
KR (1) KR20160093025A (enExample)
CN (1) CN105828821B (enExample)
AU (1) AU2014368548B2 (enExample)
CA (1) CA2933733A1 (enExample)
CL (1) CL2016001570A1 (enExample)
ES (1) ES2694352T3 (enExample)
IL (1) IL246253A0 (enExample)
MX (1) MX368870B (enExample)
RU (1) RU2679661C1 (enExample)
SG (1) SG11201604944PA (enExample)
WO (1) WO2015091833A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA45532A (fr) * 2016-07-01 2019-05-08 H Lundbeck As Schémas posologiques de la vortioxétine destinés à une apparition rapide de l'effet antidépresseur
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
AU2019376633B2 (en) 2018-11-06 2025-08-14 Purdue Pharma L.P. Compositions and methods for opioid antagonist delivery
US11266627B1 (en) 2021-05-04 2022-03-08 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
TW202345796A (zh) 2022-03-07 2023-12-01 美商健生醫藥公司 阿替卡普蘭（ａｔｉｃａｐｒａｎｔ）之形式
KR20240152410A (ko) 2022-03-07 2024-10-21 얀센 파마슈티칼즈, 인코포레이티드 아티카프란트를 포함하는 조성물

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013740A (en) 1990-03-22 1991-05-07 Hillel Glover Method for treating emotional numbness and coma
US5028612A (en) 1990-03-22 1991-07-02 Hillel Glover Method for treating emotional numbness
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
US6528518B2 (en) * 2000-12-21 2003-03-04 The Mclean Hospital Corporation Treatment of depression with kappa receptor antagonists
US20030087896A1 (en) * 2001-08-09 2003-05-08 Hillel Glover Treatment of refractory depression with an opiate antagonist and an antidepressant
JP2005508888A (ja) * 2001-08-14 2005-04-07 バイオティ セラピーズ コーポレイション アルコール依存症またはアルコール中毒を治療する方法
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
US20030181475A1 (en) 2002-03-20 2003-09-25 Euro-Celtique S.A. Method of administering buprenorphine to treat depression
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
AR058239A1 (es) * 2005-11-28 2008-01-23 Orexigen Therapeutics Inc Metodos para tratar trastornos de ansiedad
CN101432011A (zh) * 2006-02-27 2009-05-13 亚历山大·米哈洛 通过诱导逆适应调节神经递质系统的方法
WO2008066916A1 (en) 2006-11-30 2008-06-05 The Mclean Hospital Corporation Methods for the treatment of mood disorders
PL2001456T3 (pl) * 2006-04-04 2010-05-31 Emodys Gmbh Zastosowanie kompozycji zawierających antagonistę receptora opioidowego kappa do leczenia zaburzeń dysocjacyjnych
US20070259939A1 (en) * 2006-05-04 2007-11-08 Accelerated Technologies Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness
EA015287B1 (ru) 2006-06-16 2011-06-30 Х. Лундбекк А/С 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазин в качестве соединения с сочетанием активности в отношении повторного захвата серотонина, 5-нти 5-нтдля лечения когнитивного нарушения
TW200848411A (en) 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
TW200932225A (en) * 2007-12-14 2009-08-01 Lundbeck & Co As H 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine
HRP20160110T1 (hr) 2009-05-25 2016-03-11 H. Lundbeck A/S Priprema nalmefen hidroklorida iz naltreksona
US20120302590A1 (en) * 2009-08-13 2012-11-29 The General Hospital Corporation Methods and compositions to prevent addiction
KR101820181B1 (ko) 2010-04-30 2018-02-28 다케다 야쿠힌 고교 가부시키가이샤 장용성 정제
CA2815093C (en) 2010-11-05 2019-08-06 H. Lundbeck A/S Method for the manufacturing of naltrexone
CA2899455C (en) * 2013-01-30 2021-06-08 Pharmorx Therapeutics, Inc. Treatments for depression and other diseases with a low dose agent
JP6479766B2 (ja) 2013-04-17 2019-03-06 ハー・ルンドベック・アクチエゼルスカベット 不安障害患者の治療のためのナルメフェン
US20160058753A1 (en) * 2013-04-17 2016-03-03 H. Lundbeck A/S Nalmefene for Treatment of Patients with Mood Disorder

Also Published As

Publication number Publication date
SG11201604944PA (en) 2016-07-28
AU2014368548A1 (en) 2016-06-30
EP3082815B1 (en) 2018-10-03
CL2016001570A1 (es) 2016-12-09
RU2016123972A (ru) 2018-01-25
CN105828821A (zh) 2016-08-03
CN105828821B (zh) 2019-04-09
MX2016007947A (es) 2016-09-09
CA2933733A1 (en) 2015-06-25
ES2694352T3 (es) 2018-12-20
KR20160093025A (ko) 2016-08-05
US20160310488A1 (en) 2016-10-27
US10376506B2 (en) 2019-08-13
MX368870B (es) 2019-10-21
EP3082815A1 (en) 2016-10-26
JP2016540030A (ja) 2016-12-22
IL246253A0 (en) 2016-07-31
RU2679661C1 (ru) 2019-02-12
AU2014368548B2 (en) 2019-09-19
WO2015091833A1 (en) 2015-06-25

Similar Documents

Publication Publication Date Title
JP6448645B2 (ja) メランコリアの特徴を伴う抑うつ障害を処置するための、カッパ−活性を伴うオピオイド受容体拮抗薬およびボルチオキセチンの使用
JP2024091801A (ja) 物質乱用の治療方法
US11045465B2 (en) Methods and compositions to prevent addiction
WO2007005716A2 (en) Methods of treatment and compositions for use thereof
KR20080004580A (ko) 물질 남용 및 의존의 치료 방법
AU2009203070A1 (en) Dual opioid pain therapy
CA3026783A1 (en) Methods and compositions for the treatment of trauma and stressor-related disorders
ES2337622T3 (es) Uso de composiciones que contienen antagonistas del receptor opioide kappa para el tratamiento de trastornos disociativos.
JP7108041B2 (ja) 睡眠障害の治療及び予防
JP2010534674A (ja) 心的外傷後ストレス障害の治療用４−ヒドロキシ−４−メチル−ピペリジン−１−カルボン酸（４−メトキシ−７−モルホリン−４−イル−ベンゾチアゾール−２−イル）−アミド
HK1229240B (en) Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
HK1229240A1 (en) Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
CA2909504C (en) Nalmefene for treatment of patients with mood disorder
EP4065123B1 (en) Use of 2-phenyl-6-(1h-imidazol-1-yl) quinazoline for the prevention of abuse and of side effects of at least one opioid
US20110046173A1 (en) Combination analgesic opioid pain therapy
Aguilar Developing Choice: Issues and Implications of the Operant-Choice Mouse Model
JP2020517730A (ja) 心的外傷後ストレス障害を治療するための方法
Doesn't Work et al. DOSING AND USE

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180807

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181106

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181120

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181204

R150 Certificate of patent or registration of utility model

Ref document number: 6448645

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250